NYSE$MD
Pediatrix Medical Group, Inc. · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Pediatrix reported third quarter earnings, reflecting operational challenges in billing and collections and modest headwinds in volumes and payor mix.
Pediatrix Medical Group reported a net revenue of $490 million and an EPS of $0.35 for the third quarter of 2022. The company's operating results were impacted by challenges in billing and collections, as well as headwinds in volumes and payor mix. Adjusted EBITDA was reported as $58 million.
- Net revenue was $490 million.
- Income from continuing operations was $29 million.
- Adjusted EBITDA was $58 million.
- Adjusted EPS from continuing operations was $0.40.
Headline financials
Revenue & EPS history
Pediatrix · Revenue · Quarterly
$490M
Forward guidance
Pediatrix anticipates that its 2022 Adjusted EBITDA will be in a range of $240 million to $245 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
34 / 68 earnings
Positive
+31.3%
Q3 2020
Best reaction
-24.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.3% | +5.2% | +0.0% | |
| Q4 2025 | -12.2% | -8.7% | -10.3% | |
| Q3 2025 | +21.3% | +29.2% | +37.2% | |
| Q1 2025 | +12.1% | +12.2% | +7.5% | |
| Q4 2024 | +22.1% | +9.1% | +0.7% | |
| Q3 2024 | +22.9% | +30.5% | +21.4% | |
| Q2 2024 | +26.4% | +31.5% | +40.9% | |
| Q1 2024 | -8.4% | -11.4% | -25.8% | |
| Q4 2023 | -6.8% | -5.4% | +0.6% | |
| Q3 2023 | -11.7% | -11.8% | -21.8% | |
| Q2 2023 | +5.9% | +6.4% | +1.2% | |
| Q1 2023 | -2.4% | -4.5% | -5.4% | |
| Q4 2022 | +4.6% | +5.8% | -5.0% | |
| Q3 2022 | -16.2% | -18.3% | -12.6% | |
| Q2 2022 | -12.1% | -7.8% | -22.1% | |
| Q1 2022 | -18.5% | -16.6% | -14.4% | |
| Q4 2021 | -9.2% | -8.9% | -6.9% | |
| Q3 2021 | -1.2% | -3.3% | -10.7% | |
| Q2 2021 | +7.9% | +11.4% | +2.1% | |
| Q1 2021 | +19.5% | +14.8% | +19.4% | |
| Q4 2020 | -20.5% | -16.8% | -0.9% | |
| Q3 2020 | +31.3% | +32.0% | +60.5% | |
| Q2 2020 | -1.3% | -1.3% | -4.6% | |
| Q1 2020 | +5.6% | -0.7% | +38.7% | |
| Q4 2019 | -24.8% | -30.0% | -64.6% | |
| Q3 2019 | +14.6% | +18.1% | +18.9% | |
| Q2 2019 | -9.1% | -13.6% | -14.2% | |
| Q1 2019 | +3.8% | +3.8% | -12.7% | |
| Q4 2018 | -4.2% | -5.9% | -18.3% | |
| Q3 2018 | -5.0% | -4.4% | -2.6% | |
| Q2 2018 | +10.1% | +13.3% | +10.4% | |
| Q1 2018 | -4.4% | -3.6% | -1.4% | |
| Q4 2017 | +6.6% | +6.7% | +13.8% | |
| Q3 2017 | -4.9% | +0.1% | +15.6% | |
| Q2 2017 | -16.8% | -20.4% | -21.7% | |
| Q1 2017 | -8.5% | -9.9% | -8.2% | |
| Q4 2016 | -3.5% | -1.3% | +1.1% | |
| Q3 2016 | -6.3% | -6.3% | +1.3% | |
| Q2 2016 | -8.5% | -10.8% | -16.7% | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | +4.2% | — | — | |
| Q1 2015 | -1.2% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | +10.2% | — | — | |
| Q2 2014 | -4.5% | — | — | |
| Q1 2014 | -2.4% | — | — | |
| Q4 2013 | +5.0% | — | — | |
| Q3 2013 | +2.4% | — | — | |
| Q2 2013 | +1.4% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +7.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | -6.6% | — | — | |
| Q4 2011 | -1.7% | — | — | |
| Q3 2011 | +2.8% | — | — | |
| Q2 2011 | -0.9% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2011 | +4.5% | — | — | |
| Q4 2010 | +2.2% | — | — | |
| Q4 2008 | +2.2% | — | — | |
| Q3 2009 | +2.0% | — | — | |
| Q3 2010 | +2.0% | — | — | |
| Q2 2010 | +2.3% | — | — | |
| Q4 2009 | +2.3% | — | — | |
| Q2 2009 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro